Table 1.
Baseline characteristics of patients in the discovery cohort
| Characteristics | Whole cohort (n = 357) | Log-rank p | Low risk (n = 95) | High risk (n = 262) | p |
|---|---|---|---|---|---|
| Gender | 0.203 | 0.427 | |||
| Male | 242 (67.79) | 68 (71.58) | 174 (66.41) | ||
| Female | 115 (32.21) | 27 (28.42) | 88 (33.59) | ||
| Age | 0.051 | 0.391 | |||
| < 65 years | 229 (64.15) | 57 (60.00) | 172 (65.65) | ||
| ≥ 65 years | 128 (35.85) | 38 (40.00) | 90 (34.35) | ||
| TNM stage | < 0.001 | 0.004 | |||
| I | 21 (5.88) | 10 (10.53) | 11 (4.20) | ||
| II | 109 (30.53) | 37 (38.95) | 72 (27.48) | ||
| III | 227 (63.59) | 48 (50.53) | 179 (68.32) | ||
| t-SNE clustering | < 0.001 | < 0.001 | |||
| Cluster1 | 120 (33.61) | 12 (12.63) | 108 (41.22) | ||
| Cluster2 | 107 (29.97) | 26 (27.37) | 81 (30.92) | ||
| Cluster3 | 130 (36.41) | 57 (60.00) | 73 (27.86) | ||
| Hypoxia statusa | < 0.001 | < 0.001 | |||
| High | 120 (33.61) | 12 (12.63) | 108 (41.22) | ||
| Low | 130 (36.41) | 57 (60.00) | 73 (27.86) | ||
| Immune statusa | 0.005 | < 0.001 | |||
| Low | 188 (52.66) | 31 (32.63) | 157 (59.92) | ||
| High | 62 (17.37) | 38 (40.00) | 24 (9.16) | ||
| Risk group by classifier | < 0.001 | – | |||
| Low | 95 (25.3) | 95 (100.00) | 0 (0.00) | ||
| High | 262 (74.7) | 0 (0.00) | 262 (100.00) |
aPatients (n = 107) in t-SNE-derived cluster2 considered as in “moderate hypoxia status” were excluded from the comparison